Overview

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram) tablets in healthy adult volunteers and those with mild and moderate renal impairment, and examine between group comparisons.

Phase:

Phase 1

Details

Lead Sponsor:

Acorda Therapeutics

Treatments:

4-Aminopyridine